This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boswell, F. J.
Right arrow Articles by Wise, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boswell, F. J.
Right arrow Articles by Wise, R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, 06 1997, 1377-1379, Vol 41, No. 6
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram- negative organisms as demonstrated by studies of time-kill kinetics and postantibiotic effect

FJ Boswell, JM Andrews and R Wise
Department of Medical Microbiology, City Hospital NHS Trust, Birmingham, United Kingdom.

Time-kill kinetics of BAY 12-8039 were studied at two inocula against three strains each of Bacteroides fragilis, Escherichia coli, Staphylococcus aureus, Haemophilus influenzae, and Streptococcus pyogenes. The postantibiotic effects of BAY 12-8039 were studied on three strains each of E. coli, S. aureus, H. influenzae, Streptococcus pyogenes, and Streptococcus pneumoniae. The pharmacodynamic data demonstrated that BAY 12-8039 has marked activity against gram-positive and gram-negative organisms (under both anaerobic and aerobic conditions) and anaerobes. BAY 12-8039 also exhibited a postantibiotic effect of >1 h for all strains except one E. coli strain.


This article has been cited by other articles:

  • Noreddin, A. M., Haynes, V. L., Zhanel, G. G. (2005). Pharmacokinetics and Pharmacodynamics of the New Quinolones. Journal of Pharmacy Practice 18: 432-443 [Abstract]  
  • Bronner, S., Jehl, F., Peter, J.-D., Ploy, M.-C., Renault, C., Arvis, P., Monteil, H., Prevost, G. (2003). Moxifloxacin Efficacy and Vitreous Penetration in a Rabbit Model of Staphylococcus aureus Endophthalmitis and Effect on Gene Expression of Leucotoxins and Virulence Regulator Factors. Antimicrob. Agents Chemother. 47: 1621-1629 [Abstract] [Full Text]  
  • Boswell, F. J., Andrews, J. M., Jevons, G., Wise, R. (2002). Comparison of the in vitro activities of several new fluoroquinolones against respiratory pathogens and their abilities to select fluoroquinolone resistance. J Antimicrob Chemother 50: 495-502 [Abstract] [Full Text]  
  • Gehanno, P., Darantiere, S., Dubreuil, C., Chobaut, J. C., Bobin, S., Pages, J. C., Renou, G., Bobin, F., Arvis, P., Stass, H. (2002). A prospective, multicentre study of moxifloxacin concentrations in the sinus mucosa tissue of patients undergoing elective surgery of the sinus. J Antimicrob Chemother 49: 821-826 [Abstract] [Full Text]  
  • Paillard, D., Grellet, J., Dubois, V., Saux, M.-C., Quentin, C. (2002). Discrepancy between Uptake and Intracellular Activity of Moxifloxacin in a Staphylococcus aureus-Human THP-1 Monocytic Cell Model. Antimicrob. Agents Chemother. 46: 288-293 [Abstract] [Full Text]  
  • Rodriguez-Cerrato, V., McCoig, C. C., Michelow, I. C., Ghaffar, F., Jafri, H. S., Hardy, R. D., Patel, C., Olsen, K., McCracken, G. H. Jr. (2001). Pharmacodynamics and Bactericidal Activity of Moxifloxacin in Experimental Escherichia coli Meningitis. Antimicrob. Agents Chemother. 45: 3092-3097 [Abstract] [Full Text]  
  • Hamamoto, K., Shimizu, T., Fujimoto, N., Zhang, Y., Arai, S. (2001). In Vitro Activities of Moxifloxacin and Other Fluoroquinolones against Mycoplasma pneumoniae. Antimicrob. Agents Chemother. 45: 1908-1910 [Abstract] [Full Text]  
  • MacGowan, A. P., Bowker, K. E., Wootton, M., Holt, H. A. (1999). Exploration of the in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and streptococci of Lancefield Groups A and G. J Antimicrob Chemother 44: 761-766 [Abstract] [Full Text]  
  • Miyazaki, E., Miyazaki, M., Chen, J. M., Chaisson, R. E., Bishai, W. R. (1999). Moxifloxacin (BAY12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis. Antimicrob. Agents Chemother. 43: 85-89 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»